id	sid	tid	token	lemma	pos
dti-2593	1	1	dti	dti	PROPN
dti-2593	1	2	drug	drug	PROPN
dti-2593	1	3	target	target	NOUN
dti-2593	1	4	insights	insight	NOUN
dti-2593	1	5	2023	2023	NUM
dti-2593	1	6	;	;	PUNCT
dti-2593	1	7	17	17	NUM
dti-2593	1	8	:	:	SYM
dti-2593	1	9	90	90	NUM
dti-2593	1	10	-	-	SYM
dti-2593	1	11	91	91	NUM
dti-2593	1	12	issn	issn	PROPN
dti-2593	1	13	1177	1177	NUM
dti-2593	1	14	-	-	SYM
dti-2593	1	15	3928	3928	NUM
dti-2593	1	16	|	|	ADV
dti-2593	1	17	doi	doi	NOUN
dti-2593	1	18	:	:	PUNCT
dti-2593	1	19	10.33393	10.33393	NUM
dti-2593	1	20	/	/	SYM
dti-2593	1	21	dti.2023.2593	dti.2023.2593	PROPN
dti-2593	1	22	case	case	NOUN
dti-2593	1	23	report	report	NOUN
dti-2593	1	24	drug	drug	NOUN
dti-2593	1	25	target	target	NOUN
dti-2593	1	26	insights	insight	NOUN
dti-2593	1	27	issn	issn	VERB
dti-2593	1	28	1177	1177	NUM
dti-2593	1	29	-	-	SYM
dti-2593	1	30	3928	3928	NUM
dti-2593	1	31	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2593	1	32	©	©	PROPN
dti-2593	1	33	2023	2023	NUM
dti-2593	1	34	the	the	DET
dti-2593	1	35	authors	author	NOUN
dti-2593	1	36	.	.	PUNCT
dti-2593	2	1	this	this	DET
dti-2593	2	2	article	article	NOUN
dti-2593	2	3	is	be	AUX
dti-2593	2	4	published	publish	VERB
dti-2593	2	5	by	by	ADP
dti-2593	2	6	aboutscience	aboutscience	NOUN
dti-2593	2	7	and	and	CCONJ
dti-2593	2	8	licensed	license	VERB
dti-2593	2	9	under	under	ADP
dti-2593	2	10	creative	creative	ADJ
dti-2593	2	11	commons	common	NOUN
dti-2593	2	12	attribution	attribution	NOUN
dti-2593	2	13	-	-	PUNCT
dti-2593	2	14	noncommercial	noncommercial	ADJ
dti-2593	2	15	4.0	4.0	NUM
dti-2593	2	16	international	international	NOUN
dti-2593	2	17	(	(	PUNCT
dti-2593	2	18	cc	cc	NOUN
dti-2593	2	19	by	by	ADP
dti-2593	2	20	-	-	PUNCT
dti-2593	2	21	nc	nc	PROPN
dti-2593	2	22	4.0	4.0	NUM
dti-2593	2	23	)	)	PUNCT
dti-2593	2	24	.	.	PUNCT
dti-2593	3	1	commercial	commercial	ADJ
dti-2593	3	2	use	use	NOUN
dti-2593	3	3	is	be	AUX
dti-2593	3	4	not	not	PART
dti-2593	3	5	permitted	permit	VERB
dti-2593	3	6	and	and	CCONJ
dti-2593	3	7	is	be	AUX
dti-2593	3	8	subject	subject	ADJ
dti-2593	3	9	to	to	ADP
dti-2593	3	10	publisher	publisher	NOUN
dti-2593	3	11	’s	’s	PART
dti-2593	3	12	permissions	permission	NOUN
dti-2593	3	13	.	.	PUNCT
dti-2593	4	1	full	full	ADJ
dti-2593	4	2	information	information	NOUN
dti-2593	4	3	is	be	AUX
dti-2593	4	4	available	available	ADJ
dti-2593	4	5	at	at	ADP
dti-2593	4	6	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2593	4	7	activity	activity	NOUN
dti-2593	4	8	of	of	ADP
dti-2593	4	9	sotorasib	sotorasib	PROPN
dti-2593	4	10	against	against	ADP
dti-2593	4	11	brain	brain	NOUN
dti-2593	4	12	metastases	metastasis	NOUN
dti-2593	4	13	from	from	ADP
dti-2593	4	14	nsclc	nsclc	NOUN
dti-2593	4	15	harboring	harboring	NOUN
dti-2593	4	16	kras	kras	PROPN
dti-2593	4	17	p.g12c	p.g12c	PROPN
dti-2593	4	18	mutation	mutation	NOUN
dti-2593	4	19	:	:	PUNCT
dti-2593	4	20	a	a	DET
dti-2593	4	21	case	case	NOUN
dti-2593	4	22	report	report	NOUN
dti-2593	4	23	alessandro	alessandro	PROPN
dti-2593	4	24	inno1	inno1	PROPN
dti-2593	4	25	,	,	PUNCT
dti-2593	4	26	fabiana	fabiana	PROPN
dti-2593	4	27	marchetti1	marchetti1	PROPN
dti-2593	4	28	,	,	PUNCT
dti-2593	4	29	matteo	matteo	PROPN
dti-2593	4	30	valerio1	valerio1	PROPN
dti-2593	4	31	,	,	PUNCT
dti-2593	4	32	niccolò	niccolò	VERB
dti-2593	4	33	giaj	giaj	NOUN
dti-2593	4	34	levra2	levra2	PROPN
dti-2593	4	35	,	,	PUNCT
dti-2593	4	36	filippo	filippo	PROPN
dti-2593	4	37	alongi2	alongi2	PROPN
dti-2593	4	38	,	,	PUNCT
dti-2593	4	39	giovanni	giovanni	PROPN
dti-2593	4	40	foti3	foti3	PROPN
dti-2593	4	41	,	,	PUNCT
dti-2593	4	42	stefania	stefania	NOUN
dti-2593	4	43	gori1	gori1	PROPN
dti-2593	4	44	1medical	1medical	NUM
dti-2593	4	45	oncology	oncology	NOUN
dti-2593	4	46	,	,	PUNCT
dti-2593	4	47	irccs	ircc	VERB
dti-2593	4	48	ospedale	ospedale	PROPN
dti-2593	4	49	sacro	sacro	PROPN
dti-2593	4	50	cuore	cuore	PROPN
dti-2593	4	51	don	don	PROPN
dti-2593	4	52	calabria	calabria	PROPN
dti-2593	4	53	,	,	PUNCT
dti-2593	4	54	negrar	negrar	PROPN
dti-2593	4	55	di	di	X
dti-2593	4	56	valpolicella	valpolicella	PROPN
dti-2593	4	57	(	(	PUNCT
dti-2593	4	58	vr	vr	PROPN
dti-2593	4	59	)	)	PUNCT
dti-2593	4	60	italy	italy	PROPN
dti-2593	4	61	2advanced	2advanced	NUM
dti-2593	4	62	radiation	radiation	NOUN
dti-2593	4	63	oncology	oncology	NOUN
dti-2593	4	64	,	,	PUNCT
dti-2593	4	65	irccs	ircc	VERB
dti-2593	4	66	ospedale	ospedale	PROPN
dti-2593	4	67	sacro	sacro	PROPN
dti-2593	4	68	cuore	cuore	PROPN
dti-2593	4	69	don	don	PROPN
dti-2593	4	70	calabria	calabria	PROPN
dti-2593	4	71	,	,	PUNCT
dti-2593	4	72	negrar	negrar	PROPN
dti-2593	4	73	di	di	X
dti-2593	4	74	valpolicella	valpolicella	PROPN
dti-2593	4	75	(	(	PUNCT
dti-2593	4	76	vr	vr	PROPN
dti-2593	4	77	)	)	PUNCT
dti-2593	4	78	italy	italy	PROPN
dti-2593	5	1	3radiology	3radiology	PROPN
dti-2593	5	2	,	,	PUNCT
dti-2593	5	3	irccs	ircc	VERB
dti-2593	5	4	ospedale	ospedale	PROPN
dti-2593	5	5	sacro	sacro	PROPN
dti-2593	5	6	cuore	cuore	PROPN
dti-2593	5	7	don	don	PROPN
dti-2593	5	8	calabria	calabria	PROPN
dti-2593	5	9	,	,	PUNCT
dti-2593	6	1	negrar	negrar	PROPN
dti-2593	6	2	di	di	X
dti-2593	6	3	valpolicella	valpolicella	PROPN
dti-2593	6	4	(	(	PUNCT
dti-2593	6	5	vr	vr	PROPN
dti-2593	6	6	)	)	PUNCT
dti-2593	6	7	italy	italy	PROPN
dti-2593	6	8	abstract	abstract	ADJ
dti-2593	6	9	in	in	ADP
dti-2593	6	10	the	the	DET
dti-2593	6	11	codebreak	codebreak	NOUN
dti-2593	6	12	100	100	NUM
dti-2593	6	13	phase	phase	NOUN
dti-2593	6	14	2	2	NUM
dti-2593	6	15	study	study	NOUN
dti-2593	6	16	,	,	PUNCT
dti-2593	6	17	sotorasib	sotorasib	PROPN
dti-2593	6	18	was	be	AUX
dti-2593	6	19	active	active	ADJ
dti-2593	6	20	for	for	SCONJ
dti-2593	6	21	patients	patient	NOUN
dti-2593	6	22	with	with	ADP
dti-2593	6	23	metastatic	metastatic	ADJ
dti-2593	6	24	non	non	ADJ
dti-2593	6	25	-	-	ADJ
dti-2593	6	26	small	small	ADJ
dti-2593	6	27	cell	cell	NOUN
dti-2593	6	28	lung	lung	NOUN
dti-2593	6	29	cancer	cancer	NOUN
dti-2593	6	30	(	(	PUNCT
dti-2593	6	31	nsclc	nsclc	NOUN
dti-2593	6	32	)	)	PUNCT
dti-2593	6	33	harboring	harboring	NOUN
dti-2593	6	34	kirsten	kirsten	ADJ
dti-2593	6	35	rat	rat	NOUN
dti-2593	6	36	sarcoma	sarcoma	NOUN
dti-2593	6	37	viral	viral	ADJ
dti-2593	6	38	oncogene	oncogene	NOUN
dti-2593	6	39	homologue	homologue	NOUN
dti-2593	6	40	(	(	PUNCT
dti-2593	6	41	kras	kras	PROPN
dti-2593	6	42	)	)	PUNCT
dti-2593	6	43	p.g12c	p.g12c	PROPN
dti-2593	6	44	mutation	mutation	NOUN
dti-2593	6	45	.	.	PUNCT
dti-2593	7	1	however	however	ADV
dti-2593	7	2	,	,	PUNCT
dti-2593	7	3	patients	patient	NOUN
dti-2593	7	4	with	with	ADP
dti-2593	7	5	untreated	untreated	ADJ
dti-2593	7	6	and/or	and/or	CCONJ
dti-2593	7	7	active	active	ADJ
dti-2593	7	8	brain	brain	NOUN
dti-2593	7	9	metastases	metastasis	NOUN
dti-2593	7	10	were	be	AUX
dti-2593	7	11	excluded	exclude	VERB
dti-2593	7	12	from	from	ADP
dti-2593	7	13	the	the	DET
dti-2593	7	14	trial	trial	NOUN
dti-2593	7	15	,	,	PUNCT
dti-2593	7	16	and	and	CCONJ
dti-2593	7	17	the	the	DET
dti-2593	7	18	activity	activity	NOUN
dti-2593	7	19	of	of	ADP
dti-2593	7	20	sotorasib	sotorasib	PROPN
dti-2593	7	21	in	in	ADP
dti-2593	7	22	the	the	DET
dti-2593	7	23	setting	setting	NOUN
dti-2593	7	24	of	of	ADP
dti-2593	7	25	brain	brain	NOUN
dti-2593	7	26	metastases	metastasis	NOUN
dti-2593	7	27	should	should	AUX
dti-2593	7	28	be	be	AUX
dti-2593	7	29	further	far	ADV
dti-2593	7	30	investigated	investigate	VERB
dti-2593	7	31	.	.	PUNCT
dti-2593	8	1	here	here	ADV
dti-2593	8	2	we	we	PRON
dti-2593	8	3	report	report	VERB
dti-2593	8	4	the	the	DET
dti-2593	8	5	case	case	NOUN
dti-2593	8	6	of	of	ADP
dti-2593	8	7	a	a	DET
dti-2593	8	8	kras	kras	PROPN
dti-2593	8	9	p.g12c	p.g12c	PROPN
dti-2593	8	10	mutant	mutant	ADJ
dti-2593	8	11	nsclc	nsclc	NOUN
dti-2593	8	12	patient	patient	NOUN
dti-2593	8	13	with	with	ADP
dti-2593	8	14	three	three	NUM
dti-2593	8	15	brain	brain	NOUN
dti-2593	8	16	metastases	metastasis	NOUN
dti-2593	8	17	,	,	PUNCT
dti-2593	8	18	of	of	ADP
dti-2593	8	19	whom	whom	PRON
dti-2593	8	20	one	one	NUM
dti-2593	8	21	was	be	AUX
dti-2593	8	22	untreated	untreated	ADJ
dti-2593	8	23	and	and	CCONJ
dti-2593	8	24	the	the	DET
dti-2593	8	25	other	other	ADJ
dti-2593	8	26	two	two	NUM
dti-2593	8	27	had	have	AUX
dti-2593	8	28	progressed	progress	VERB
dti-2593	8	29	after	after	ADP
dti-2593	8	30	radiotherapy	radiotherapy	NOUN
dti-2593	8	31	with	with	ADP
dti-2593	8	32	symptoms	symptom	NOUN
dti-2593	8	33	requiring	require	VERB
dti-2593	8	34	steroids	steroid	NOUN
dti-2593	8	35	,	,	PUNCT
dti-2593	8	36	that	that	PRON
dti-2593	8	37	responded	respond	VERB
dti-2593	8	38	to	to	ADP
dti-2593	8	39	sotorasib	sotorasib	PROPN
dti-2593	8	40	.	.	PUNCT
dti-2593	9	1	our	our	PRON
dti-2593	9	2	report	report	NOUN
dti-2593	9	3	suggests	suggest	VERB
dti-2593	9	4	that	that	SCONJ
dti-2593	9	5	sotorasib	sotorasib	PROPN
dti-2593	9	6	may	may	AUX
dti-2593	9	7	be	be	AUX
dti-2593	9	8	active	active	ADJ
dti-2593	9	9	against	against	ADP
dti-2593	9	10	untreated	untreated	ADJ
dti-2593	9	11	or	or	CCONJ
dti-2593	9	12	progressive	progressive	ADJ
dti-2593	9	13	brain	brain	NOUN
dti-2593	9	14	metastases	metastasis	NOUN
dti-2593	9	15	,	,	PUNCT
dti-2593	9	16	supporting	support	VERB
dti-2593	9	17	further	further	ADJ
dti-2593	9	18	evaluation	evaluation	NOUN
dti-2593	9	19	of	of	ADP
dti-2593	9	20	sotorasib	sotorasib	PROPN
dti-2593	9	21	in	in	ADP
dti-2593	9	22	this	this	DET
dti-2593	9	23	setting	setting	NOUN
dti-2593	9	24	.	.	PUNCT
dti-2593	10	1	keywords	keyword	NOUN
dti-2593	10	2	:	:	PUNCT
dti-2593	10	3	brain	brain	NOUN
dti-2593	10	4	metastases	metastasis	NOUN
dti-2593	10	5	,	,	PUNCT
dti-2593	10	6	central	central	ADJ
dti-2593	10	7	nervous	nervous	ADJ
dti-2593	10	8	system	system	NOUN
dti-2593	10	9	,	,	PUNCT
dti-2593	10	10	kras	kras	PROPN
dti-2593	10	11	,	,	PUNCT
dti-2593	10	12	nsclc	nsclc	NOUN
dti-2593	10	13	,	,	PUNCT
dti-2593	10	14	sotorasib	sotorasib	PROPN
dti-2593	10	15	received	receive	VERB
dti-2593	10	16	:	:	PUNCT
dti-2593	10	17	april	april	PROPN
dti-2593	10	18	27	27	NUM
dti-2593	10	19	,	,	PUNCT
dti-2593	10	20	2023	2023	NUM
dti-2593	10	21	accepted	accept	VERB
dti-2593	10	22	:	:	PUNCT
dti-2593	10	23	may	may	AUX
dti-2593	10	24	22	22	NUM
dti-2593	10	25	,	,	PUNCT
dti-2593	10	26	2023	2023	NUM
dti-2593	10	27	published	publish	VERB
dti-2593	10	28	online	online	ADV
dti-2593	10	29	:	:	PUNCT
dti-2593	10	30	june	june	PROPN
dti-2593	10	31	20	20	NUM
dti-2593	10	32	,	,	PUNCT
dti-2593	10	33	2023	2023	NUM
dti-2593	10	34	corresponding	correspond	VERB
dti-2593	10	35	author	author	NOUN
dti-2593	10	36	:	:	PUNCT
dti-2593	10	37	alessandro	alessandro	PROPN
dti-2593	10	38	inno	inno	PROPN
dti-2593	10	39	medical	medical	ADJ
dti-2593	10	40	oncology	oncology	NOUN
dti-2593	10	41	irccs	ircc	VERB
dti-2593	10	42	ospedale	ospedale	PROPN
dti-2593	10	43	sacro	sacro	PROPN
dti-2593	10	44	cuore	cuore	PROPN
dti-2593	10	45	don	don	PROPN
dti-2593	10	46	calabria	calabria	PROPN
dti-2593	10	47	via	via	ADP
dti-2593	10	48	don	don	PROPN
dti-2593	10	49	a.	a.	NOUN
dti-2593	10	50	sempreboni	sempreboni	NOUN
dti-2593	10	51	5	5	NUM
dti-2593	10	52	37024	37024	NUM
dti-2593	10	53	negrar	negrar	PROPN
dti-2593	10	54	di	di	X
dti-2593	10	55	valpolicella	valpolicella	PROPN
dti-2593	10	56	(	(	PUNCT
dti-2593	10	57	vr	vr	PROPN
dti-2593	10	58	)	)	PUNCT
dti-2593	10	59	italy	italy	PROPN
dti-2593	10	60	alessandro.inno@sacrocuore.it	alessandro.inno@sacrocuore.it	PROPN
dti-2593	10	61	rearrangements	rearrangement	NOUN
dti-2593	10	62	,	,	PUNCT
dti-2593	10	63	target	target	NOUN
dti-2593	10	64	therapy	therapy	NOUN
dti-2593	10	65	achieves	achieve	VERB
dti-2593	10	66	high	high	ADJ
dti-2593	10	67	intracranial	intracranial	ADJ
dti-2593	10	68	response	response	NOUN
dti-2593	10	69	rate	rate	NOUN
dti-2593	10	70	(	(	PUNCT
dti-2593	10	71	4,5	4,5	NUM
dti-2593	10	72	)	)	PUNCT
dti-2593	10	73	.	.	PUNCT
dti-2593	11	1	however	however	ADV
dti-2593	11	2	,	,	PUNCT
dti-2593	11	3	there	there	PRON
dti-2593	11	4	is	be	VERB
dti-2593	11	5	still	still	ADV
dti-2593	11	6	paucity	paucity	NOUN
dti-2593	11	7	of	of	ADP
dti-2593	11	8	data	datum	NOUN
dti-2593	11	9	regarding	regard	VERB
dti-2593	11	10	the	the	DET
dti-2593	11	11	activity	activity	NOUN
dti-2593	11	12	of	of	ADP
dti-2593	11	13	sotorasib	sotorasib	PROPN
dti-2593	11	14	against	against	ADP
dti-2593	11	15	brain	brain	NOUN
dti-2593	11	16	metastases	metastasis	NOUN
dti-2593	11	17	from	from	ADP
dti-2593	11	18	kras	kras	PROPN
dti-2593	11	19	p.g12c	p.g12c	PROPN
dti-2593	11	20	mutant	mutant	ADJ
dti-2593	11	21	nsclc	nsclc	NOUN
dti-2593	11	22	.	.	PUNCT
dti-2593	12	1	in	in	ADP
dti-2593	12	2	fact	fact	NOUN
dti-2593	12	3	,	,	PUNCT
dti-2593	12	4	although	although	SCONJ
dti-2593	12	5	in	in	ADP
dti-2593	12	6	the	the	DET
dti-2593	12	7	codebreak	codebreak	NOUN
dti-2593	12	8	100	100	NUM
dti-2593	12	9	trial	trial	NOUN
dti-2593	12	10	approximately	approximately	ADV
dti-2593	12	11	20	20	NUM
dti-2593	12	12	%	%	NOUN
dti-2593	12	13	of	of	ADP
dti-2593	12	14	patients	patient	NOUN
dti-2593	12	15	had	have	VERB
dti-2593	12	16	brain	brain	NOUN
dti-2593	12	17	metastases	metastasis	NOUN
dti-2593	12	18	at	at	ADP
dti-2593	12	19	baseline	baseline	NOUN
dti-2593	12	20	,	,	PUNCT
dti-2593	12	21	patients	patient	NOUN
dti-2593	12	22	with	with	ADP
dti-2593	12	23	active	active	ADJ
dti-2593	12	24	untreated	untreated	ADJ
dti-2593	12	25	brain	brain	NOUN
dti-2593	12	26	metastases	metastasis	NOUN
dti-2593	12	27	were	be	AUX
dti-2593	12	28	excluded	exclude	VERB
dti-2593	12	29	from	from	ADP
dti-2593	12	30	the	the	DET
dti-2593	12	31	trial	trial	NOUN
dti-2593	12	32	.	.	PUNCT
dti-2593	13	1	more	more	ADV
dti-2593	13	2	recently	recently	ADV
dti-2593	13	3	,	,	PUNCT
dti-2593	13	4	a	a	DET
dti-2593	13	5	retrospective	retrospective	ADJ
dti-2593	13	6	study	study	NOUN
dti-2593	13	7	reported	report	VERB
dti-2593	13	8	six	six	NUM
dti-2593	13	9	patients	patient	NOUN
dti-2593	13	10	with	with	ADP
dti-2593	13	11	active	active	ADJ
dti-2593	13	12	untreated	untreated	ADJ
dti-2593	13	13	brain	brain	NOUN
dti-2593	13	14	metastases	metastasis	NOUN
dti-2593	13	15	receiving	receive	VERB
dti-2593	13	16	sotorasib	sotorasib	NOUN
dti-2593	13	17	.	.	PUNCT
dti-2593	14	1	among	among	ADP
dti-2593	14	2	four	four	NUM
dti-2593	14	3	patients	patient	NOUN
dti-2593	14	4	evaluable	evaluable	ADJ
dti-2593	14	5	for	for	ADP
dti-2593	14	6	response	response	NOUN
dti-2593	14	7	,	,	PUNCT
dti-2593	14	8	confirmed	confirm	VERB
dti-2593	14	9	intracranial	intracranial	ADJ
dti-2593	14	10	response	response	NOUN
dti-2593	14	11	to	to	ADP
dti-2593	14	12	sotorasib	sotorasib	PROPN
dti-2593	14	13	was	be	AUX
dti-2593	14	14	observed	observe	VERB
dti-2593	14	15	in	in	ADP
dti-2593	14	16	three	three	NUM
dti-2593	14	17	patients	patient	NOUN
dti-2593	14	18	,	,	PUNCT
dti-2593	14	19	with	with	ADP
dti-2593	14	20	a	a	DET
dti-2593	14	21	median	median	ADJ
dti-2593	14	22	duration	duration	NOUN
dti-2593	14	23	of	of	ADP
dti-2593	14	24	response	response	NOUN
dti-2593	14	25	of	of	ADP
dti-2593	14	26	4.1	4.1	NUM
dti-2593	14	27	months	month	NOUN
dti-2593	14	28	,	,	PUNCT
dti-2593	14	29	and	and	CCONJ
dti-2593	14	30	a	a	DET
dti-2593	14	31	median	median	ADJ
dti-2593	14	32	intracranial	intracranial	ADJ
dti-2593	14	33	progression	progression	NOUN
dti-2593	14	34	-	-	PUNCT
dti-2593	14	35	free	free	ADJ
dti-2593	14	36	survival	survival	NOUN
dti-2593	14	37	of	of	ADP
dti-2593	14	38	4.7	4.7	NUM
dti-2593	14	39	months	month	NOUN
dti-2593	14	40	(	(	PUNCT
dti-2593	14	41	6	6	NUM
dti-2593	14	42	)	)	PUNCT
dti-2593	14	43	.	.	PUNCT
dti-2593	15	1	here	here	ADV
dti-2593	15	2	we	we	PRON
dti-2593	15	3	report	report	VERB
dti-2593	15	4	a	a	DET
dti-2593	15	5	case	case	NOUN
dti-2593	15	6	of	of	ADP
dti-2593	15	7	a	a	DET
dti-2593	15	8	patient	patient	NOUN
dti-2593	15	9	with	with	ADP
dti-2593	15	10	metastatic	metastatic	ADJ
dti-2593	15	11	,	,	PUNCT
dti-2593	15	12	kras	kras	PROPN
dti-2593	15	13	p.g12c	p.g12c	PROPN
dti-2593	15	14	mutant	mutant	ADJ
dti-2593	15	15	nsclc	nsclc	NOUN
dti-2593	15	16	with	with	ADP
dti-2593	15	17	both	both	PRON
dti-2593	15	18	treated	treat	VERB
dti-2593	15	19	and	and	CCONJ
dti-2593	15	20	untreated	untreate	VERB
dti-2593	15	21	active	active	ADJ
dti-2593	15	22	brain	brain	NOUN
dti-2593	15	23	metastases	metastasis	NOUN
dti-2593	15	24	receiving	receive	VERB
dti-2593	15	25	sotorasib	sotorasib	NOUN
dti-2593	15	26	as	as	ADP
dti-2593	15	27	second	second	ADJ
dti-2593	15	28	-	-	PUNCT
dti-2593	15	29	line	line	NOUN
dti-2593	15	30	therapy	therapy	NOUN
dti-2593	15	31	.	.	PUNCT
dti-2593	16	1	case	case	NOUN
dti-2593	16	2	report	report	NOUN
dti-2593	16	3	in	in	ADP
dti-2593	16	4	june	june	PROPN
dti-2593	16	5	2017	2017	NUM
dti-2593	16	6	,	,	PUNCT
dti-2593	16	7	a	a	DET
dti-2593	16	8	72	72	NUM
dti-2593	16	9	-	-	PUNCT
dti-2593	16	10	year	year	NOUN
dti-2593	16	11	-	-	PUNCT
dti-2593	16	12	old	old	ADJ
dti-2593	16	13	former	former	ADJ
dti-2593	16	14	caucasian	caucasian	ADJ
dti-2593	16	15	female	female	ADJ
dti-2593	16	16	smoker	smoker	NOUN
dti-2593	16	17	underwent	undergo	VERB
dti-2593	16	18	upper	upper	ADJ
dti-2593	16	19	right	right	ADJ
dti-2593	16	20	lung	lung	NOUN
dti-2593	16	21	lobectomy	lobectomy	NOUN
dti-2593	16	22	with	with	ADP
dti-2593	16	23	regional	regional	ADJ
dti-2593	16	24	nodal	nodal	NOUN
dti-2593	16	25	dissection	dissection	NOUN
dti-2593	16	26	for	for	ADP
dti-2593	16	27	lung	lung	NOUN
dti-2593	16	28	adenocarcinoma	adenocarcinoma	NOUN
dti-2593	16	29	,	,	PUNCT
dti-2593	16	30	stage	stage	NOUN
dti-2593	16	31	pt2a	pt2a	ADJ
dti-2593	16	32	pn1	pn1	NOUN
dti-2593	16	33	.	.	PUNCT
dti-2593	17	1	comorbidities	comorbiditie	NOUN
dti-2593	17	2	were	be	AUX
dti-2593	17	3	:	:	PUNCT
dti-2593	17	4	previous	previous	ADJ
dti-2593	17	5	left	leave	VERB
dti-2593	17	6	nephrectomy	nephrectomy	ADV
dti-2593	17	7	for	for	ADP
dti-2593	17	8	clear	clear	ADJ
dti-2593	17	9	cell	cell	NOUN
dti-2593	17	10	renal	renal	ADJ
dti-2593	17	11	carcinoma	carcinoma	NOUN
dti-2593	17	12	,	,	PUNCT
dti-2593	17	13	hypertension	hypertension	NOUN
dti-2593	17	14	,	,	PUNCT
dti-2593	17	15	type	type	NOUN
dti-2593	17	16	2	2	NUM
dti-2593	17	17	diabetes	diabetes	NOUN
dti-2593	17	18	,	,	PUNCT
dti-2593	17	19	and	and	CCONJ
dti-2593	17	20	meningioma	meningioma	NOUN
dti-2593	17	21	.	.	PUNCT
dti-2593	18	1	molecular	molecular	ADJ
dti-2593	18	2	profile	profile	NOUN
dti-2593	18	3	of	of	ADP
dti-2593	18	4	nsclc	nsclc	NOUN
dti-2593	18	5	was	be	AUX
dti-2593	18	6	:	:	PUNCT
dti-2593	18	7	egfr	egfr	VERB
dti-2593	18	8	wild	wild	ADJ
dti-2593	18	9	type	type	NOUN
dti-2593	18	10	,	,	PUNCT
dti-2593	18	11	alk	alk	VERB
dti-2593	18	12	negative	negative	ADJ
dti-2593	18	13	,	,	PUNCT
dti-2593	18	14	ros1	ros1	PROPN
dti-2593	18	15	negative	negative	ADJ
dti-2593	18	16	,	,	PUNCT
dti-2593	18	17	programmed	program	VERB
dti-2593	18	18	death	death	NOUN
dti-2593	18	19	ligand	ligand	NOUN
dti-2593	18	20	(	(	PUNCT
dti-2593	18	21	pdl	pdl	NOUN
dti-2593	18	22	)	)	PUNCT
dti-2593	18	23	tumor	tumor	NOUN
dti-2593	18	24	proportion	proportion	NOUN
dti-2593	18	25	score	score	NOUN
dti-2593	18	26	(	(	PUNCT
dti-2593	18	27	tps	tps	NOUN
dti-2593	18	28	)	)	PUNCT
dti-2593	18	29	<	<	X
dti-2593	18	30	1	1	NUM
dti-2593	18	31	%	%	NOUN
dti-2593	18	32	,	,	PUNCT
dti-2593	18	33	kras	kras	PROPN
dti-2593	18	34	mutant	mutant	PROPN
dti-2593	18	35	p.g12c	p.g12c	PROPN
dti-2593	18	36	.	.	PUNCT
dti-2593	19	1	at	at	ADP
dti-2593	19	2	baseline	baseline	NOUN
dti-2593	19	3	staging	staging	NOUN
dti-2593	19	4	,	,	PUNCT
dti-2593	19	5	patient	patient	NOUN
dti-2593	19	6	also	also	ADV
dti-2593	19	7	had	have	VERB
dti-2593	19	8	two	two	NUM
dti-2593	19	9	synchronous	synchronous	ADJ
dti-2593	19	10	intracranial	intracranial	ADJ
dti-2593	19	11	metastases	metastasis	NOUN
dti-2593	19	12	,	,	PUNCT
dti-2593	19	13	in	in	ADP
dti-2593	19	14	right	right	ADJ
dti-2593	19	15	parietal	parietal	ADJ
dti-2593	19	16	lobe	lobe	NOUN
dti-2593	19	17	and	and	CCONJ
dti-2593	19	18	in	in	ADP
dti-2593	19	19	right	right	PROPN
dti-2593	19	20	cerebellar	cerebellar	PROPN
dti-2593	19	21	hemisphere	hemisphere	ADV
dti-2593	19	22	,	,	PUNCT
dti-2593	19	23	both	both	PRON
dti-2593	19	24	treated	treat	VERB
dti-2593	19	25	with	with	ADP
dti-2593	19	26	stereotactic	stereotactic	ADJ
dti-2593	19	27	radiosurgery	radiosurgery	NOUN
dti-2593	19	28	(	(	PUNCT
dti-2593	19	29	21	21	NUM
dti-2593	19	30	gy	gy	NOUN
dti-2593	19	31	as	as	ADP
dti-2593	19	32	single	single	ADJ
dti-2593	19	33	fraction	fraction	NOUN
dti-2593	19	34	)	)	PUNCT
dti-2593	19	35	.	.	PUNCT
dti-2593	20	1	the	the	DET
dti-2593	20	2	patient	patient	NOUN
dti-2593	20	3	also	also	ADV
dti-2593	20	4	received	receive	VERB
dti-2593	20	5	background	background	NOUN
dti-2593	20	6	about	about	ADP
dti-2593	20	7	25	25	NUM
dti-2593	20	8	-	-	SYM
dti-2593	20	9	30	30	NUM
dti-2593	20	10	%	%	NOUN
dti-2593	20	11	of	of	ADP
dti-2593	20	12	non	non	ADJ
dti-2593	20	13	-	-	ADJ
dti-2593	20	14	small	small	ADJ
dti-2593	20	15	cell	cell	NOUN
dti-2593	20	16	lung	lung	NOUN
dti-2593	20	17	cancers	cancer	NOUN
dti-2593	20	18	(	(	PUNCT
dti-2593	20	19	nsclcs	nsclcs	NOUN
dti-2593	20	20	)	)	PUNCT
dti-2593	20	21	harbor	harbor	VERB
dti-2593	20	22	a	a	DET
dti-2593	20	23	mutation	mutation	NOUN
dti-2593	20	24	in	in	ADP
dti-2593	20	25	the	the	DET
dti-2593	20	26	kirsten	kirsten	ADJ
dti-2593	20	27	rat	rat	NOUN
dti-2593	20	28	sarcoma	sarcoma	NOUN
dti-2593	20	29	viral	viral	ADJ
dti-2593	20	30	oncogene	oncogene	NOUN
dti-2593	20	31	homologue	homologue	NOUN
dti-2593	20	32	(	(	PUNCT
dti-2593	20	33	kras	kras	PROPN
dti-2593	20	34	)	)	PUNCT
dti-2593	20	35	gene	gene	NOUN
dti-2593	20	36	.	.	PUNCT
dti-2593	21	1	particularly	particularly	ADV
dti-2593	21	2	,	,	PUNCT
dti-2593	21	3	kras	kras	PROPN
dti-2593	21	4	p.g12c	p.g12c	PROPN
dti-2593	21	5	mutation	mutation	NOUN
dti-2593	21	6	is	be	AUX
dti-2593	21	7	the	the	DET
dti-2593	21	8	most	most	ADV
dti-2593	21	9	frequent	frequent	ADJ
dti-2593	21	10	kras	kra	NOUN
dti-2593	21	11	mutation	mutation	NOUN
dti-2593	21	12	and	and	CCONJ
dti-2593	21	13	it	it	PRON
dti-2593	21	14	is	be	AUX
dti-2593	21	15	found	find	VERB
dti-2593	21	16	in	in	ADP
dti-2593	21	17	approximatively	approximatively	ADV
dti-2593	21	18	13	13	NUM
dti-2593	21	19	%	%	NOUN
dti-2593	21	20	of	of	ADP
dti-2593	21	21	nsclc	nsclc	NOUN
dti-2593	21	22	(	(	PUNCT
dti-2593	21	23	1	1	NUM
dti-2593	21	24	)	)	PUNCT
dti-2593	21	25	.	.	PUNCT
dti-2593	22	1	sotorasib	sotorasib	PROPN
dti-2593	22	2	,	,	PUNCT
dti-2593	22	3	a	a	DET
dti-2593	22	4	specific	specific	ADJ
dti-2593	22	5	inhibitor	inhibitor	NOUN
dti-2593	22	6	of	of	ADP
dti-2593	22	7	kras	kras	PROPN
dti-2593	22	8	p.g12c	p.g12c	PROPN
dti-2593	22	9	mutation	mutation	NOUN
dti-2593	22	10	,	,	PUNCT
dti-2593	22	11	has	have	AUX
dti-2593	22	12	demonstrated	demonstrate	VERB
dti-2593	22	13	activity	activity	NOUN
dti-2593	22	14	in	in	ADP
dti-2593	22	15	pretreated	pretreate	VERB
dti-2593	22	16	metastatic	metastatic	ADJ
dti-2593	22	17	nsclc	nsclc	NOUN
dti-2593	22	18	patients	patient	NOUN
dti-2593	22	19	.	.	PUNCT
dti-2593	23	1	in	in	ADP
dti-2593	23	2	the	the	DET
dti-2593	23	3	codebreak	codebreak	NOUN
dti-2593	23	4	100	100	NUM
dti-2593	23	5	trial	trial	NOUN
dti-2593	23	6	,	,	PUNCT
dti-2593	23	7	a	a	DET
dti-2593	23	8	single	single	ADJ
dti-2593	23	9	-	-	PUNCT
dti-2593	23	10	group	group	NOUN
dti-2593	23	11	phase	phase	NOUN
dti-2593	23	12	2	2	NUM
dti-2593	23	13	study	study	NOUN
dti-2593	23	14	on	on	ADP
dti-2593	23	15	126	126	NUM
dti-2593	23	16	pretreated	pretreate	VERB
dti-2593	23	17	patients	patient	NOUN
dti-2593	23	18	with	with	ADP
dti-2593	23	19	metastatic	metastatic	ADJ
dti-2593	23	20	,	,	PUNCT
dti-2593	23	21	kras	kras	PROPN
dti-2593	23	22	p.g12c	p.g12c	PROPN
dti-2593	23	23	mutant	mutant	ADJ
dti-2593	23	24	nsclc	nsclc	NOUN
dti-2593	23	25	,	,	PUNCT
dti-2593	23	26	sotorasib	sotorasib	PROPN
dti-2593	23	27	led	lead	VERB
dti-2593	23	28	to	to	ADP
dti-2593	23	29	a	a	DET
dti-2593	23	30	response	response	NOUN
dti-2593	23	31	rate	rate	NOUN
dti-2593	23	32	of	of	ADP
dti-2593	23	33	37.1	37.1	NUM
dti-2593	23	34	%	%	NOUN
dti-2593	23	35	(	(	PUNCT
dti-2593	23	36	95	95	NUM
dti-2593	23	37	%	%	NOUN
dti-2593	23	38	confidence	confidence	NOUN
dti-2593	23	39	interval	interval	NOUN
dti-2593	23	40	(	(	PUNCT
dti-2593	23	41	ci	ci	NOUN
dti-2593	23	42	)	)	PUNCT
dti-2593	23	43	,	,	PUNCT
dti-2593	23	44	28.646.2	28.646.2	NUM
dti-2593	23	45	)	)	PUNCT
dti-2593	23	46	,	,	PUNCT
dti-2593	23	47	a	a	DET
dti-2593	23	48	median	median	ADJ
dti-2593	23	49	progression	progression	NOUN
dti-2593	23	50	-	-	PUNCT
dti-2593	23	51	free	free	ADJ
dti-2593	23	52	survival	survival	NOUN
dti-2593	23	53	of	of	ADP
dti-2593	23	54	6.8	6.8	NUM
dti-2593	23	55	months	month	NOUN
dti-2593	23	56	(	(	PUNCT
dti-2593	23	57	95	95	NUM
dti-2593	23	58	%	%	NOUN
dti-2593	23	59	ci	ci	NOUN
dti-2593	23	60	,	,	PUNCT
dti-2593	23	61	5.1	5.1	NUM
dti-2593	23	62	-	-	SYM
dti-2593	23	63	8.2	8.2	NUM
dti-2593	23	64	)	)	PUNCT
dti-2593	23	65	,	,	PUNCT
dti-2593	23	66	and	and	CCONJ
dti-2593	23	67	a	a	DET
dti-2593	23	68	median	median	ADJ
dti-2593	23	69	overall	overall	ADJ
dti-2593	23	70	survival	survival	NOUN
dti-2593	23	71	of	of	ADP
dti-2593	23	72	12.5	12.5	NUM
dti-2593	23	73	months	month	NOUN
dti-2593	23	74	(	(	PUNCT
dti-2593	23	75	95	95	NUM
dti-2593	23	76	%	%	NOUN
dti-2593	23	77	ci	ci	NOUN
dti-2593	23	78	,	,	PUNCT
dti-2593	23	79	10.0	10.0	NUM
dti-2593	23	80	-	-	PUNCT
dti-2593	23	81	not	not	PART
dti-2593	23	82	reached	reach	VERB
dti-2593	23	83	)	)	PUNCT
dti-2593	23	84	,	,	PUNCT
dti-2593	23	85	with	with	ADP
dti-2593	23	86	an	an	DET
dti-2593	23	87	acceptable	acceptable	ADJ
dti-2593	23	88	safety	safety	NOUN
dti-2593	23	89	profile	profile	NOUN
dti-2593	23	90	(	(	PUNCT
dti-2593	23	91	2	2	NUM
dti-2593	23	92	)	)	PUNCT
dti-2593	23	93	.	.	PUNCT
dti-2593	24	1	brain	brain	NOUN
dti-2593	24	2	metastases	metastasis	NOUN
dti-2593	24	3	represent	represent	VERB
dti-2593	24	4	a	a	DET
dti-2593	24	5	frequent	frequent	ADJ
dti-2593	24	6	complication	complication	NOUN
dti-2593	24	7	of	of	ADP
dti-2593	24	8	nsclc	nsclc	NOUN
dti-2593	24	9	.	.	PUNCT
dti-2593	25	1	they	they	PRON
dti-2593	25	2	are	be	AUX
dti-2593	25	3	associated	associate	VERB
dti-2593	25	4	with	with	ADP
dti-2593	25	5	deterioration	deterioration	NOUN
dti-2593	25	6	of	of	ADP
dti-2593	25	7	quality	quality	NOUN
dti-2593	25	8	of	of	ADP
dti-2593	25	9	life	life	NOUN
dti-2593	25	10	,	,	PUNCT
dti-2593	25	11	poor	poor	ADJ
dti-2593	25	12	prognosis	prognosis	NOUN
dti-2593	25	13	,	,	PUNCT
dti-2593	25	14	and	and	CCONJ
dti-2593	25	15	low	low	ADJ
dti-2593	25	16	response	response	NOUN
dti-2593	25	17	rates	rate	NOUN
dti-2593	25	18	to	to	ADP
dti-2593	25	19	chemotherapy	chemotherapy	NOUN
dti-2593	25	20	(	(	PUNCT
dti-2593	25	21	3	3	NUM
dti-2593	25	22	)	)	PUNCT
dti-2593	25	23	.	.	PUNCT
dti-2593	26	1	for	for	ADP
dti-2593	26	2	patients	patient	NOUN
dti-2593	26	3	with	with	ADP
dti-2593	26	4	brain	brain	NOUN
dti-2593	26	5	metastases	metastasis	NOUN
dti-2593	26	6	from	from	ADP
dti-2593	26	7	oncogene	oncogene	NOUN
dti-2593	26	8	addicted	addict	VERB
dti-2593	26	9	nsclc	nsclc	NOUN
dti-2593	26	10	,	,	PUNCT
dti-2593	26	11	such	such	ADJ
dti-2593	26	12	as	as	ADP
dti-2593	26	13	tumors	tumor	NOUN
dti-2593	26	14	with	with	ADP
dti-2593	26	15	egfr	egfr	ADJ
dti-2593	26	16	mutations	mutation	NOUN
dti-2593	26	17	or	or	CCONJ
dti-2593	26	18	alk	alk	VERB
dti-2593	26	19	https://doi.org/10.33393/10.33393/dti.2023.2593	https://doi.org/10.33393/10.33393/dti.2023.2593	PROPN
dti-2593	26	20	https://creativecommons.org/licenses/by-nc/4.0/legalcode	https://creativecommons.org/licenses/by-nc/4.0/legalcode	NUM
dti-2593	26	21	mailto:alessandro.inno@sacrocuore.it	mailto:alessandro.inno@sacrocuore.it	PROPN
dti-2593	26	22	inno	inno	NOUN
dti-2593	26	23	et	et	PROPN
dti-2593	26	24	al	al	PROPN
dti-2593	26	25	drug	drug	PROPN
dti-2593	26	26	target	target	NOUN
dti-2593	26	27	insights	insight	NOUN
dti-2593	26	28	2023	2023	NUM
dti-2593	26	29	;	;	PUNCT
dti-2593	26	30	17	17	NUM
dti-2593	26	31	:	:	SYM
dti-2593	26	32	91	91	NUM
dti-2593	26	33	©	©	PROPN
dti-2593	26	34	2023	2023	NUM
dti-2593	26	35	the	the	DET
dti-2593	26	36	authors	author	NOUN
dti-2593	26	37	.	.	PUNCT
dti-2593	27	1	published	publish	VERB
dti-2593	27	2	by	by	ADP
dti-2593	27	3	aboutscience	aboutscience	NOUN
dti-2593	27	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2593	27	5	first	first	ADJ
dti-2593	27	6	-	-	PUNCT
dti-2593	27	7	line	line	NOUN
dti-2593	27	8	chemotherapy	chemotherapy	NOUN
dti-2593	27	9	with	with	ADP
dti-2593	27	10	carboplatin	carboplatin	NOUN
dti-2593	27	11	plus	plus	CCONJ
dti-2593	27	12	paclitaxel	paclitaxel	NOUN
dti-2593	27	13	for	for	ADP
dti-2593	27	14	four	four	NUM
dti-2593	27	15	courses	course	NOUN
dti-2593	27	16	,	,	PUNCT
dti-2593	27	17	from	from	ADP
dti-2593	27	18	august	august	PROPN
dti-2593	27	19	to	to	ADP
dti-2593	27	20	october	october	PROPN
dti-2593	27	21	2017	2017	NUM
dti-2593	27	22	.	.	PUNCT
dti-2593	28	1	during	during	ADP
dti-2593	28	2	the	the	DET
dti-2593	28	3	following	follow	VERB
dti-2593	28	4	surveillance	surveillance	NOUN
dti-2593	28	5	program	program	NOUN
dti-2593	28	6	,	,	PUNCT
dti-2593	28	7	the	the	DET
dti-2593	28	8	patient	patient	NOUN
dti-2593	28	9	developed	develop	VERB
dti-2593	28	10	two	two	NUM
dti-2593	28	11	lung	lung	NOUN
dti-2593	28	12	metastases	metastasis	NOUN
dti-2593	28	13	in	in	ADP
dti-2593	28	14	the	the	DET
dti-2593	28	15	right	right	ADJ
dti-2593	28	16	middle	middle	PROPN
dti-2593	28	17	lobe	lobe	PROPN
dti-2593	28	18	(	(	PUNCT
dti-2593	28	19	march	march	PROPN
dti-2593	28	20	2018	2018	NUM
dti-2593	28	21	)	)	PUNCT
dti-2593	28	22	both	both	PRON
dti-2593	28	23	treated	treat	VERB
dti-2593	28	24	with	with	ADP
dti-2593	28	25	stereotactic	stereotactic	PROPN
dti-2593	28	26	radiotherapy	radiotherapy	NOUN
dti-2593	28	27	(	(	PUNCT
dti-2593	28	28	70	70	NUM
dti-2593	28	29	gy	gy	NOUN
dti-2593	28	30	in	in	ADP
dti-2593	28	31	10	10	NUM
dti-2593	28	32	fractions	fraction	NOUN
dti-2593	28	33	)	)	PUNCT
dti-2593	28	34	,	,	PUNCT
dti-2593	28	35	a	a	DET
dti-2593	28	36	further	further	ADJ
dti-2593	28	37	histology	histology	NOUN
dti-2593	28	38	-	-	PUNCT
dti-2593	28	39	proven	prove	VERB
dti-2593	28	40	,	,	PUNCT
dti-2593	28	41	adenocarcinoma	adenocarcinoma	NOUN
dti-2593	28	42	lung	lung	NOUN
dti-2593	28	43	metastasis	metastasis	NOUN
dti-2593	28	44	kras	kra	NOUN
dti-2593	28	45	mutant	mutant	ADJ
dti-2593	28	46	p.g12c	p.g12c	PROPN
dti-2593	28	47	in	in	ADP
dti-2593	28	48	upper	upper	ADJ
dti-2593	28	49	left	left	NOUN
dti-2593	28	50	lobe	lobe	NOUN
dti-2593	28	51	(	(	PUNCT
dti-2593	28	52	september	september	PROPN
dti-2593	28	53	2019	2019	NUM
dti-2593	28	54	)	)	PUNCT
dti-2593	28	55	also	also	ADV
dti-2593	28	56	treated	treat	VERB
dti-2593	28	57	with	with	ADP
dti-2593	28	58	stereotactic	stereotactic	PROPN
dti-2593	28	59	radiotherapy	radiotherapy	NOUN
dti-2593	28	60	(	(	PUNCT
dti-2593	28	61	60	60	NUM
dti-2593	28	62	gy	gy	NOUN
dti-2593	28	63	in	in	ADP
dti-2593	28	64	10	10	NUM
dti-2593	28	65	fractions	fraction	NOUN
dti-2593	28	66	)	)	PUNCT
dti-2593	28	67	,	,	PUNCT
dti-2593	28	68	and	and	CCONJ
dti-2593	28	69	progressive	progressive	ADJ
dti-2593	28	70	right	right	ADJ
dti-2593	28	71	parietal	parietal	ADJ
dti-2593	28	72	and	and	CCONJ
dti-2593	28	73	right	right	ADJ
dti-2593	28	74	cerebellar	cerebellar	ADJ
dti-2593	28	75	metastases	metastasis	NOUN
dti-2593	28	76	treated	treat	VERB
dti-2593	28	77	with	with	ADP
dti-2593	28	78	further	further	ADJ
dti-2593	28	79	radiation	radiation	NOUN
dti-2593	28	80	therapy	therapy	NOUN
dti-2593	28	81	,	,	PUNCT
dti-2593	28	82	respectively	respectively	ADV
dti-2593	28	83	21	21	NUM
dti-2593	28	84	gy	gy	NOUN
dti-2593	28	85	in	in	ADP
dti-2593	28	86	three	three	NUM
dti-2593	28	87	fractions	fraction	NOUN
dti-2593	28	88	and	and	CCONJ
dti-2593	28	89	27	27	NUM
dti-2593	28	90	gy	gy	NOUN
dti-2593	28	91	in	in	ADP
dti-2593	28	92	three	three	NUM
dti-2593	28	93	fractions	fraction	NOUN
dti-2593	28	94	.	.	PUNCT
dti-2593	29	1	in	in	ADP
dti-2593	29	2	march	march	PROPN
dti-2593	29	3	2021	2021	NUM
dti-2593	29	4	the	the	DET
dti-2593	29	5	patient	patient	NOUN
dti-2593	29	6	experienced	experience	VERB
dti-2593	29	7	symptomatic	symptomatic	ADJ
dti-2593	29	8	intracranial	intracranial	ADJ
dti-2593	29	9	disease	disease	NOUN
dti-2593	29	10	progression	progression	NOUN
dti-2593	29	11	,	,	PUNCT
dti-2593	29	12	with	with	ADP
dti-2593	29	13	a	a	DET
dti-2593	29	14	new	new	ADJ
dti-2593	29	15	brain	brain	NOUN
dti-2593	29	16	metastasis	metastasis	NOUN
dti-2593	29	17	in	in	ADP
dti-2593	29	18	the	the	DET
dti-2593	29	19	right	right	ADJ
dti-2593	29	20	frontal	frontal	ADJ
dti-2593	29	21	lobe	lobe	NOUN
dti-2593	29	22	and	and	CCONJ
dti-2593	29	23	increase	increase	VERB
dti-2593	29	24	in	in	ADP
dti-2593	29	25	size	size	NOUN
dti-2593	29	26	of	of	ADP
dti-2593	29	27	the	the	DET
dti-2593	29	28	other	other	ADJ
dti-2593	29	29	two	two	NUM
dti-2593	29	30	known	know	VERB
dti-2593	29	31	metastases	metastasis	NOUN
dti-2593	29	32	and	and	CCONJ
dti-2593	29	33	appearance	appearance	NOUN
dti-2593	29	34	of	of	ADP
dti-2593	29	35	surrounding	surround	VERB
dti-2593	29	36	edema	edema	NOUN
dti-2593	29	37	in	in	ADP
dti-2593	29	38	the	the	DET
dti-2593	29	39	right	right	ADJ
dti-2593	29	40	parietal	parietal	ADJ
dti-2593	29	41	lobe	lobe	NOUN
dti-2593	29	42	,	,	PUNCT
dti-2593	29	43	requiring	require	VERB
dti-2593	29	44	steroid	steroid	NOUN
dti-2593	29	45	therapy	therapy	NOUN
dti-2593	29	46	.	.	PUNCT
dti-2593	30	1	positron	positron	NOUN
dti-2593	30	2	emission	emission	NOUN
dti-2593	30	3	tomography	tomography	NOUN
dti-2593	30	4	(	(	PUNCT
dti-2593	30	5	pet)/computed	pet)/compute	VERB
dti-2593	30	6	tomography	tomography	NOUN
dti-2593	30	7	(	(	PUNCT
dti-2593	30	8	ct	ct	PROPN
dti-2593	30	9	)	)	PUNCT
dti-2593	30	10	scan	scan	NOUN
dti-2593	30	11	did	do	AUX
dti-2593	30	12	not	not	PART
dti-2593	30	13	show	show	VERB
dti-2593	30	14	extracranial	extracranial	ADJ
dti-2593	30	15	disease	disease	NOUN
dti-2593	30	16	.	.	PUNCT
dti-2593	31	1	the	the	DET
dti-2593	31	2	patient	patient	NOUN
dti-2593	31	3	was	be	AUX
dti-2593	31	4	started	start	VERB
dti-2593	31	5	on	on	ADP
dti-2593	31	6	sotorasib	sotorasib	PROPN
dti-2593	31	7	,	,	PUNCT
dti-2593	31	8	and	and	CCONJ
dti-2593	31	9	the	the	DET
dti-2593	31	10	brain	brain	NOUN
dti-2593	31	11	magnetic	magnetic	ADJ
dti-2593	31	12	resonance	resonance	NOUN
dti-2593	31	13	imaging	imaging	NOUN
dti-2593	31	14	(	(	PUNCT
dti-2593	31	15	mri	mri	NOUN
dti-2593	31	16	)	)	PUNCT
dti-2593	31	17	after	after	ADP
dti-2593	31	18	2	2	NUM
dti-2593	31	19	months	month	NOUN
dti-2593	31	20	of	of	ADP
dti-2593	31	21	treatment	treatment	NOUN
dti-2593	31	22	showed	show	VERB
dti-2593	31	23	stability	stability	NOUN
dti-2593	31	24	of	of	ADP
dti-2593	31	25	the	the	DET
dti-2593	31	26	cerebellar	cerebellar	ADJ
dti-2593	31	27	metastasis	metastasis	NOUN
dti-2593	31	28	,	,	PUNCT
dti-2593	31	29	reduction	reduction	NOUN
dti-2593	31	30	in	in	ADP
dti-2593	31	31	size	size	NOUN
dti-2593	31	32	of	of	ADP
dti-2593	31	33	the	the	DET
dti-2593	31	34	previously	previously	ADV
dti-2593	31	35	treated	treat	VERB
dti-2593	31	36	parietal	parietal	ADJ
dti-2593	31	37	right	right	ADJ
dti-2593	31	38	metastasis	metastasis	NOUN
dti-2593	31	39	with	with	ADP
dti-2593	31	40	improvement	improvement	NOUN
dti-2593	31	41	of	of	ADP
dti-2593	31	42	the	the	DET
dti-2593	31	43	surrounding	surround	VERB
dti-2593	31	44	edema	edema	NOUN
dti-2593	31	45	,	,	PUNCT
dti-2593	31	46	reduction	reduction	NOUN
dti-2593	31	47	in	in	ADP
dti-2593	31	48	size	size	NOUN
dti-2593	31	49	of	of	ADP
dti-2593	31	50	the	the	DET
dti-2593	31	51	previously	previously	ADV
dti-2593	31	52	untreated	untreated	ADJ
dti-2593	31	53	right	right	ADJ
dti-2593	31	54	frontal	frontal	ADJ
dti-2593	31	55	lobe	lobe	VERB
dti-2593	31	56	metastasis	metastasis	NOUN
dti-2593	31	57	,	,	PUNCT
dti-2593	31	58	and	and	CCONJ
dti-2593	31	59	no	no	DET
dti-2593	31	60	appearance	appearance	NOUN
dti-2593	31	61	of	of	ADP
dti-2593	31	62	new	new	ADJ
dti-2593	31	63	brain	brain	NOUN
dti-2593	31	64	metastases	metastasis	NOUN
dti-2593	31	65	(	(	PUNCT
dti-2593	31	66	fig	fig	NOUN
dti-2593	31	67	.	.	PUNCT
dti-2593	32	1	1	1	NUM
dti-2593	32	2	)	)	PUNCT
dti-2593	32	3	.	.	PUNCT
dti-2593	33	1	in	in	ADP
dti-2593	33	2	march	march	PROPN
dti-2593	33	3	2022	2022	NUM
dti-2593	33	4	posterior	posterior	ADJ
dti-2593	33	5	fossa	fossa	ADJ
dti-2593	33	6	hemorrhage	hemorrhage	NOUN
dti-2593	33	7	occurred	occur	VERB
dti-2593	33	8	due	due	ADP
dti-2593	33	9	to	to	ADP
dti-2593	33	10	bleeding	bleeding	NOUN
dti-2593	33	11	of	of	ADP
dti-2593	33	12	the	the	DET
dti-2593	33	13	cerebellar	cerebellar	ADJ
dti-2593	33	14	metastasis	metastasis	NOUN
dti-2593	33	15	,	,	PUNCT
dti-2593	33	16	which	which	PRON
dti-2593	33	17	was	be	AUX
dti-2593	33	18	treated	treat	VERB
dti-2593	33	19	with	with	ADP
dti-2593	33	20	surgical	surgical	ADJ
dti-2593	33	21	evacuation	evacuation	NOUN
dti-2593	33	22	of	of	ADP
dti-2593	33	23	the	the	DET
dti-2593	33	24	hemorrhagic	hemorrhagic	NOUN
dti-2593	33	25	focus	focus	NOUN
dti-2593	33	26	and	and	CCONJ
dti-2593	33	27	metastasectomy	metastasectomy	NOUN
dti-2593	33	28	.	.	PUNCT
dti-2593	34	1	histology	histology	NOUN
dti-2593	34	2	examination	examination	NOUN
dti-2593	34	3	of	of	ADP
dti-2593	34	4	the	the	DET
dti-2593	34	5	cerebellar	cerebellar	ADJ
dti-2593	34	6	metastasis	metastasis	NOUN
dti-2593	34	7	revealed	reveal	VERB
dti-2593	34	8	radionecrosis	radionecrosis	NOUN
dti-2593	34	9	with	with	ADP
dti-2593	34	10	no	no	DET
dti-2593	34	11	residual	residual	ADJ
dti-2593	34	12	viable	viable	ADJ
dti-2593	34	13	cancer	cancer	NOUN
dti-2593	34	14	tissue	tissue	NOUN
dti-2593	34	15	.	.	PUNCT
dti-2593	35	1	treatment	treatment	NOUN
dti-2593	35	2	with	with	ADP
dti-2593	35	3	sotorasib	sotorasib	PROPN
dti-2593	35	4	was	be	AUX
dti-2593	35	5	continued	continue	VERB
dti-2593	35	6	and	and	CCONJ
dti-2593	35	7	the	the	DET
dti-2593	35	8	disease	disease	NOUN
dti-2593	35	9	remained	remain	VERB
dti-2593	35	10	stable	stable	ADJ
dti-2593	35	11	until	until	ADP
dti-2593	35	12	july	july	PROPN
dti-2593	35	13	2022	2022	NUM
dti-2593	35	14	when	when	SCONJ
dti-2593	35	15	brain	brain	NOUN
dti-2593	35	16	mri	mri	NOUN
dti-2593	35	17	showed	show	VERB
dti-2593	35	18	oligoprogression	oligoprogression	NOUN
dti-2593	35	19	due	due	ADJ
dti-2593	35	20	to	to	PART
dti-2593	35	21	increase	increase	VERB
dti-2593	35	22	in	in	ADP
dti-2593	35	23	size	size	NOUN
dti-2593	35	24	of	of	ADP
dti-2593	35	25	the	the	DET
dti-2593	35	26	right	right	ADJ
dti-2593	35	27	frontal	frontal	ADJ
dti-2593	35	28	metastasis	metastasis	NOUN
dti-2593	35	29	,	,	PUNCT
dti-2593	35	30	which	which	PRON
dti-2593	35	31	was	be	AUX
dti-2593	35	32	treated	treat	VERB
dti-2593	35	33	with	with	ADP
dti-2593	35	34	stereotactic	stereotactic	PROPN
dti-2593	35	35	radiotherapy	radiotherapy	NOUN
dti-2593	35	36	(	(	PUNCT
dti-2593	35	37	24	24	NUM
dti-2593	35	38	gy	gy	NOUN
dti-2593	35	39	in	in	ADP
dti-2593	35	40	three	three	NUM
dti-2593	35	41	fractions	fraction	NOUN
dti-2593	35	42	)	)	PUNCT
dti-2593	35	43	.	.	PUNCT
dti-2593	36	1	sotorasib	sotorasib	PROPN
dti-2593	36	2	was	be	AUX
dti-2593	36	3	continued	continue	VERB
dti-2593	36	4	and	and	CCONJ
dti-2593	36	5	,	,	PUNCT
dti-2593	36	6	after	after	ADP
dti-2593	36	7	27	27	NUM
dti-2593	36	8	months	month	NOUN
dti-2593	36	9	(	(	PUNCT
dti-2593	36	10	may	may	PROPN
dti-2593	36	11	2023	2023	NUM
dti-2593	36	12	)	)	PUNCT
dti-2593	36	13	,	,	PUNCT
dti-2593	36	14	treatment	treatment	NOUN
dti-2593	36	15	is	be	AUX
dti-2593	36	16	still	still	ADV
dti-2593	36	17	ongoing	ongoing	ADJ
dti-2593	36	18	,	,	PUNCT
dti-2593	36	19	without	without	ADP
dti-2593	36	20	safety	safety	NOUN
dti-2593	36	21	concerns	concern	NOUN
dti-2593	36	22	,	,	PUNCT
dti-2593	36	23	and	and	CCONJ
dti-2593	36	24	with	with	ADP
dti-2593	36	25	stable	stable	ADJ
dti-2593	36	26	intracranial	intracranial	ADJ
dti-2593	36	27	disease	disease	NOUN
dti-2593	36	28	at	at	ADP
dti-2593	36	29	brain	brain	NOUN
dti-2593	36	30	mri	mri	NOUN
dti-2593	36	31	and	and	CCONJ
dti-2593	36	32	still	still	ADV
dti-2593	36	33	no	no	DET
dti-2593	36	34	evidence	evidence	NOUN
dti-2593	36	35	of	of	ADP
dti-2593	36	36	extracranial	extracranial	ADJ
dti-2593	36	37	metastases	metastasis	NOUN
dti-2593	36	38	at	at	ADP
dti-2593	36	39	the	the	DET
dti-2593	36	40	pet	pet	NOUN
dti-2593	36	41	/	/	SYM
dti-2593	36	42	ct	ct	PROPN
dti-2593	36	43	scan	scan	NOUN
dti-2593	36	44	.	.	PUNCT
dti-2593	37	1	conclusion	conclusion	NOUN
dti-2593	37	2	we	we	PRON
dti-2593	37	3	have	have	AUX
dti-2593	37	4	reported	report	VERB
dti-2593	37	5	a	a	DET
dti-2593	37	6	case	case	NOUN
dti-2593	37	7	of	of	ADP
dti-2593	37	8	intracranial	intracranial	ADJ
dti-2593	37	9	response	response	NOUN
dti-2593	37	10	to	to	ADP
dti-2593	37	11	sotorasib	sotorasib	PROPN
dti-2593	37	12	in	in	ADP
dti-2593	37	13	a	a	DET
dti-2593	37	14	patient	patient	NOUN
dti-2593	37	15	with	with	ADP
dti-2593	37	16	both	both	CCONJ
dti-2593	37	17	pretreated	pretreate	VERB
dti-2593	37	18	and	and	CCONJ
dti-2593	37	19	untreated	untreated	ADJ
dti-2593	37	20	symptomatic	symptomatic	ADJ
dti-2593	37	21	brain	brain	NOUN
dti-2593	37	22	metastases	metastasis	NOUN
dti-2593	37	23	from	from	ADP
dti-2593	37	24	kras	kras	PROPN
dti-2593	37	25	p.g12c	p.g12c	PROPN
dti-2593	37	26	mutant	mutant	ADJ
dti-2593	37	27	nsclc	nsclc	NOUN
dti-2593	37	28	,	,	PUNCT
dti-2593	37	29	with	with	ADP
dti-2593	37	30	a	a	DET
dti-2593	37	31	duration	duration	NOUN
dti-2593	37	32	of	of	ADP
dti-2593	37	33	intracranial	intracranial	ADJ
dti-2593	37	34	response	response	NOUN
dti-2593	37	35	of	of	ADP
dti-2593	37	36	16	16	NUM
dti-2593	37	37	months	month	NOUN
dti-2593	37	38	.	.	PUNCT
dti-2593	38	1	an	an	DET
dti-2593	38	2	oligoprogressive	oligoprogressive	ADJ
dti-2593	38	3	brain	brain	NOUN
dti-2593	38	4	metastasis	metastasis	NOUN
dti-2593	38	5	was	be	AUX
dti-2593	38	6	successfully	successfully	ADV
dti-2593	38	7	managed	manage	VERB
dti-2593	38	8	with	with	ADP
dti-2593	38	9	stereotactic	stereotactic	PROPN
dti-2593	38	10	radiotherapy	radiotherapy	NOUN
dti-2593	38	11	while	while	SCONJ
dti-2593	38	12	continuing	continue	VERB
dti-2593	38	13	sorafenib	sorafenib	NOUN
dti-2593	38	14	,	,	PUNCT
dti-2593	38	15	with	with	ADP
dti-2593	38	16	a	a	DET
dti-2593	38	17	time	time	NOUN
dti-2593	38	18	to	to	ADP
dti-2593	38	19	treatment	treatment	NOUN
dti-2593	38	20	failure	failure	NOUN
dti-2593	38	21	exceeding	exceed	VERB
dti-2593	38	22	27	27	NUM
dti-2593	38	23	months	month	NOUN
dti-2593	38	24	.	.	PUNCT
dti-2593	39	1	this	this	DET
dti-2593	39	2	report	report	NOUN
dti-2593	39	3	supports	support	VERB
dti-2593	39	4	further	further	ADJ
dti-2593	39	5	investigation	investigation	NOUN
dti-2593	39	6	of	of	ADP
dti-2593	39	7	sotorasib	sotorasib	PROPN
dti-2593	39	8	in	in	ADP
dti-2593	39	9	the	the	DET
dti-2593	39	10	setting	setting	NOUN
dti-2593	39	11	of	of	ADP
dti-2593	39	12	kras	kras	PROPN
dti-2593	39	13	p.g12c	p.g12c	PROPN
dti-2593	39	14	mutant	mutant	ADJ
dti-2593	39	15	nsclc	nsclc	NOUN
dti-2593	39	16	with	with	ADP
dti-2593	39	17	untreated	untreated	ADJ
dti-2593	39	18	brain	brain	NOUN
dti-2593	39	19	metastases	metastasis	NOUN
dti-2593	39	20	.	.	PUNCT
dti-2593	40	1	disclosures	disclosure	NOUN
dti-2593	40	2	conflict	conflict	NOUN
dti-2593	40	3	of	of	ADP
dti-2593	40	4	interest	interest	NOUN
dti-2593	40	5	:	:	PUNCT
dti-2593	40	6	the	the	DET
dti-2593	40	7	authors	author	NOUN
dti-2593	40	8	declare	declare	VERB
dti-2593	40	9	no	no	DET
dti-2593	40	10	conflict	conflict	NOUN
dti-2593	40	11	of	of	ADP
dti-2593	40	12	interest	interest	NOUN
dti-2593	40	13	.	.	PUNCT
dti-2593	41	1	financial	financial	ADJ
dti-2593	41	2	support	support	NOUN
dti-2593	41	3	:	:	PUNCT
dti-2593	41	4	this	this	DET
dti-2593	41	5	research	research	NOUN
dti-2593	41	6	received	receive	VERB
dti-2593	41	7	no	no	DET
dti-2593	41	8	specific	specific	ADJ
dti-2593	41	9	grant	grant	NOUN
dti-2593	41	10	from	from	ADP
dti-2593	41	11	any	any	DET
dti-2593	41	12	funding	funding	NOUN
dti-2593	41	13	agency	agency	NOUN
dti-2593	41	14	in	in	ADP
dti-2593	41	15	the	the	DET
dti-2593	41	16	public	public	ADJ
dti-2593	41	17	,	,	PUNCT
dti-2593	41	18	commercial	commercial	ADJ
dti-2593	41	19	,	,	PUNCT
dti-2593	41	20	or	or	CCONJ
dti-2593	41	21	not	not	PART
dti-2593	41	22	-	-	PUNCT
dti-2593	41	23	for	for	ADP
dti-2593	41	24	-	-	PUNCT
dti-2593	41	25	profit	profit	NOUN
dti-2593	41	26	sectors	sector	NOUN
dti-2593	41	27	.	.	PUNCT
dti-2593	42	1	authors	author	NOUN
dti-2593	42	2	contribution	contribution	VERB
dti-2593	42	3	:	:	PUNCT
dti-2593	42	4	all	all	DET
dti-2593	42	5	authors	author	NOUN
dti-2593	42	6	contributed	contribute	VERB
dti-2593	42	7	equally	equally	ADV
dti-2593	42	8	to	to	ADP
dti-2593	42	9	this	this	DET
dti-2593	42	10	manuscript	manuscript	NOUN
dti-2593	42	11	.	.	PUNCT
dti-2593	43	1	references	reference	NOUN
dti-2593	43	2	1	1	NUM
dti-2593	43	3	.	.	PUNCT
dti-2593	43	4	thai	thai	PROPN
dti-2593	43	5	aa	aa	PROPN
dti-2593	43	6	,	,	PUNCT
dti-2593	43	7	solomon	solomon	PROPN
dti-2593	43	8	bj	bj	PROPN
dti-2593	43	9	,	,	PUNCT
dti-2593	43	10	sequist	sequist	PROPN
dti-2593	43	11	lv	lv	PROPN
dti-2593	43	12	,	,	PUNCT
dti-2593	43	13	gainor	gainor	PROPN
dti-2593	43	14	jf	jf	PROPN
dti-2593	43	15	,	,	PUNCT
dti-2593	43	16	heist	heist	NOUN
dti-2593	43	17	rs	rs	NOUN
dti-2593	43	18	.	.	PUNCT
dti-2593	44	1	lung	lung	NOUN
dti-2593	44	2	cancer	cancer	NOUN
dti-2593	44	3	.	.	PUNCT
dti-2593	45	1	lancet	lancet	NOUN
dti-2593	45	2	.	.	PUNCT
dti-2593	46	1	2021;398(10299):535	2021;398(10299):535	NUM
dti-2593	46	2	-	-	SYM
dti-2593	46	3	554	554	NUM
dti-2593	46	4	.	.	PUNCT
dti-2593	47	1	crossref	crossref	PROPN
dti-2593	47	2	pubmed	pubmed	PROPN
dti-2593	47	3	2	2	NUM
dti-2593	47	4	.	.	PUNCT
dti-2593	48	1	skoulidis	skoulidis	PROPN
dti-2593	48	2	f	f	PROPN
dti-2593	48	3	,	,	PUNCT
dti-2593	48	4	li	li	PROPN
dti-2593	48	5	bt	bt	PROPN
dti-2593	48	6	,	,	PUNCT
dti-2593	48	7	dy	dy	PROPN
dti-2593	48	8	gk	gk	PROPN
dti-2593	48	9	,	,	PUNCT
dti-2593	48	10	et	et	PROPN
dti-2593	48	11	al	al	PROPN
dti-2593	48	12	.	.	PROPN
dti-2593	48	13	sotorasib	sotorasib	PROPN
dti-2593	48	14	for	for	ADP
dti-2593	48	15	lung	lung	NOUN
dti-2593	48	16	cancers	cancer	NOUN
dti-2593	48	17	with	with	ADP
dti-2593	48	18	kras	kras	PROPN
dti-2593	48	19	p.g12c	p.g12c	PROPN
dti-2593	48	20	mutation	mutation	NOUN
dti-2593	48	21	.	.	PUNCT
dti-2593	49	1	n	n	PROPN
dti-2593	49	2	engl	engl	PROPN
dti-2593	49	3	j	j	PROPN
dti-2593	49	4	med	med	PROPN
dti-2593	49	5	.	.	PUNCT
dti-2593	50	1	2021;384(25):23712381	2021;384(25):23712381	X
dti-2593	50	2	.	.	PUNCT
dti-2593	51	1	crossref	crossref	PROPN
dti-2593	51	2	pubmed	pubmed	PROPN
dti-2593	51	3	3	3	PROPN
dti-2593	51	4	.	.	PUNCT
dti-2593	52	1	inno	inno	PROPN
dti-2593	52	2	a	a	PROPN
dti-2593	52	3	,	,	PUNCT
dti-2593	52	4	di	di	PROPN
dti-2593	52	5	noia	noia	PROPN
dti-2593	52	6	v	v	PROPN
dti-2593	52	7	,	,	PUNCT
dti-2593	52	8	d’argento	d’argento	NOUN
dti-2593	52	9	e	e	PROPN
dti-2593	52	10	,	,	PUNCT
dti-2593	52	11	modena	modena	PROPN
dti-2593	52	12	a	a	PROPN
dti-2593	52	13	,	,	PUNCT
dti-2593	52	14	gori	gori	PROPN
dti-2593	52	15	s.	s.	PROPN
dti-2593	52	16	state	state	PROPN
dti-2593	52	17	of	of	ADP
dti-2593	52	18	the	the	DET
dti-2593	52	19	art	art	NOUN
dti-2593	52	20	of	of	ADP
dti-2593	52	21	chemotherapy	chemotherapy	NOUN
dti-2593	52	22	for	for	ADP
dti-2593	52	23	the	the	DET
dti-2593	52	24	treatment	treatment	NOUN
dti-2593	52	25	of	of	ADP
dti-2593	52	26	central	central	ADJ
dti-2593	52	27	nervous	nervous	ADJ
dti-2593	52	28	system	system	NOUN
dti-2593	52	29	metastases	metastasis	NOUN
dti-2593	52	30	from	from	ADP
dti-2593	52	31	non	non	ADJ
dti-2593	52	32	-	-	ADJ
dti-2593	52	33	small	small	ADJ
dti-2593	52	34	cell	cell	NOUN
dti-2593	52	35	lung	lung	NOUN
dti-2593	52	36	cancer	cancer	NOUN
dti-2593	52	37	.	.	PUNCT
dti-2593	53	1	transl	transl	PROPN
dti-2593	53	2	lung	lung	PROPN
dti-2593	53	3	cancer	cancer	NOUN
dti-2593	53	4	res	re	NOUN
dti-2593	53	5	.	.	PUNCT
dti-2593	54	1	2016;5(6):599	2016;5(6):599	NUM
dti-2593	54	2	-	-	SYM
dti-2593	54	3	609	609	NUM
dti-2593	54	4	.	.	PUNCT
dti-2593	55	1	crossref	crossref	PROPN
dti-2593	55	2	pubmed	pubmed	PROPN
dti-2593	55	3	4	4	PROPN
dti-2593	55	4	.	.	PUNCT
dti-2593	55	5	reungwetwattana	reungwetwattana	PROPN
dti-2593	55	6	t	t	PROPN
dti-2593	55	7	,	,	PUNCT
dti-2593	55	8	nakagawa	nakagawa	PROPN
dti-2593	55	9	k	k	PROPN
dti-2593	55	10	,	,	PUNCT
dti-2593	55	11	cho	cho	PROPN
dti-2593	55	12	bc	bc	PROPN
dti-2593	55	13	,	,	PUNCT
dti-2593	55	14	et	et	PROPN
dti-2593	55	15	al	al	PROPN
dti-2593	55	16	.	.	PUNCT
dti-2593	56	1	cns	cns	PROPN
dti-2593	56	2	response	response	NOUN
dti-2593	56	3	to	to	ADP
dti-2593	56	4	osimertinib	osimertinib	NOUN
dti-2593	56	5	versus	versus	ADP
dti-2593	56	6	standard	standard	ADJ
dti-2593	56	7	epidermal	epidermal	ADJ
dti-2593	56	8	growth	growth	NOUN
dti-2593	56	9	factor	factor	NOUN
dti-2593	56	10	receptor	receptor	NOUN
dti-2593	56	11	tyrosine	tyrosine	PROPN
dti-2593	56	12	kinase	kinase	VERB
dti-2593	56	13	inhibitors	inhibitor	NOUN
dti-2593	56	14	in	in	ADP
dti-2593	56	15	patients	patient	NOUN
dti-2593	56	16	with	with	ADP
dti-2593	56	17	untreated	untreated	ADJ
dti-2593	56	18	egfrmutated	egfrmutate	VERB
dti-2593	56	19	advanced	advanced	ADJ
dti-2593	56	20	non	non	ADJ
dti-2593	56	21	-	-	ADJ
dti-2593	56	22	small	small	ADJ
dti-2593	56	23	-	-	PUNCT
dti-2593	56	24	cell	cell	NOUN
dti-2593	56	25	lung	lung	NOUN
dti-2593	56	26	cancer	cancer	NOUN
dti-2593	56	27	.	.	PUNCT
dti-2593	57	1	j	j	PROPN
dti-2593	57	2	clin	clin	PROPN
dti-2593	57	3	oncol	oncol	PROPN
dti-2593	57	4	.	.	PUNCT
dti-2593	58	1	2018;jco2018783118(33):jco2018783118	2018;jco2018783118(33):jco2018783118	NUM
dti-2593	58	2	.	.	PUNCT
dti-2593	59	1	crossref	crossref	PROPN
dti-2593	59	2	pubmed	pubmed	PROPN
dti-2593	59	3	5	5	NUM
dti-2593	59	4	.	.	PUNCT
dti-2593	60	1	gadgeel	gadgeel	PROPN
dti-2593	60	2	s	s	PART
dti-2593	60	3	,	,	PUNCT
dti-2593	60	4	peters	peters	PROPN
dti-2593	60	5	s	s	PROPN
dti-2593	60	6	,	,	PUNCT
dti-2593	60	7	mok	mok	PROPN
dti-2593	60	8	t	t	PROPN
dti-2593	60	9	,	,	PUNCT
dti-2593	60	10	et	et	PROPN
dti-2593	60	11	al	al	PROPN
dti-2593	60	12	.	.	PUNCT
dti-2593	60	13	alectinib	alectinib	NOUN
dti-2593	60	14	versus	versus	ADP
dti-2593	60	15	crizotinib	crizotinib	VERB
dti-2593	60	16	in	in	ADP
dti-2593	60	17	treatment	treatment	NOUN
dti-2593	60	18	-	-	PUNCT
dti-2593	60	19	naive	naive	ADJ
dti-2593	60	20	anaplastic	anaplastic	ADJ
dti-2593	60	21	lymphoma	lymphoma	NOUN
dti-2593	60	22	kinase	kinase	NOUN
dti-2593	60	23	-	-	PUNCT
dti-2593	60	24	positive	positive	ADJ
dti-2593	60	25	(	(	PUNCT
dti-2593	60	26	alk+	alk+	NOUN
dti-2593	60	27	)	)	PUNCT
dti-2593	60	28	non	non	ADJ
dti-2593	60	29	-	-	ADJ
dti-2593	60	30	small	small	ADJ
dti-2593	60	31	-	-	PUNCT
dti-2593	60	32	cell	cell	NOUN
dti-2593	60	33	lung	lung	NOUN
dti-2593	60	34	cancer	cancer	NOUN
dti-2593	60	35	:	:	PUNCT
dti-2593	60	36	cns	cns	PROPN
dti-2593	60	37	efficacy	efficacy	NOUN
dti-2593	60	38	results	result	NOUN
dti-2593	60	39	from	from	ADP
dti-2593	60	40	the	the	DET
dti-2593	60	41	alex	alex	PROPN
dti-2593	60	42	study	study	PROPN
dti-2593	60	43	.	.	PUNCT
dti-2593	61	1	ann	ann	PROPN
dti-2593	61	2	oncol	oncol	PROPN
dti-2593	61	3	.	.	PUNCT
dti-2593	62	1	2018;29(11):2214	2018;29(11):2214	NUM
dti-2593	62	2	-	-	SYM
dti-2593	62	3	2222	2222	NUM
dti-2593	62	4	.	.	PUNCT
dti-2593	63	1	crossref	crossref	PROPN
dti-2593	63	2	pubmed	pubmed	PROPN
dti-2593	63	3	6	6	NUM
dti-2593	63	4	.	.	PUNCT
dti-2593	63	5	lamberti	lamberti	PROPN
dti-2593	63	6	g	g	PROPN
dti-2593	63	7	,	,	PUNCT
dti-2593	63	8	aizer	aizer	NOUN
dti-2593	63	9	a	a	NOUN
dti-2593	63	10	,	,	PUNCT
dti-2593	63	11	ricciuti	ricciuti	NOUN
dti-2593	63	12	b	b	PROPN
dti-2593	63	13	,	,	PUNCT
dti-2593	63	14	et	et	PROPN
dti-2593	63	15	al	al	PROPN
dti-2593	63	16	.	.	PROPN
dti-2593	63	17	incidence	incidence	NOUN
dti-2593	63	18	of	of	ADP
dti-2593	63	19	brain	brain	NOUN
dti-2593	63	20	metastases	metastasis	NOUN
dti-2593	63	21	and	and	CCONJ
dti-2593	63	22	preliminary	preliminary	ADJ
dti-2593	63	23	evidence	evidence	NOUN
dti-2593	63	24	of	of	ADP
dti-2593	63	25	intracranial	intracranial	ADJ
dti-2593	63	26	activity	activity	NOUN
dti-2593	63	27	with	with	ADP
dti-2593	63	28	sotorasib	sotorasib	PROPN
dti-2593	63	29	in	in	ADP
dti-2593	63	30	patients	patient	NOUN
dti-2593	63	31	with	with	ADP
dti-2593	63	32	krasg12c	krasg12c	ADJ
dti-2593	63	33	-	-	PUNCT
dti-2593	63	34	mutant	mutant	ADJ
dti-2593	63	35	non	non	ADJ
dti-2593	63	36	-	-	ADJ
dti-2593	63	37	small	small	ADJ
dti-2593	63	38	-	-	PUNCT
dti-2593	63	39	cell	cell	NOUN
dti-2593	63	40	lung	lung	NOUN
dti-2593	63	41	cancer	cancer	NOUN
dti-2593	63	42	.	.	PUNCT
dti-2593	64	1	jco	jco	PROPN
dti-2593	64	2	precis	precis	PROPN
dti-2593	64	3	oncol	oncol	PROPN
dti-2593	64	4	.	.	PUNCT
dti-2593	65	1	2023;7(7):e2200621	2023;7(7):e2200621	NUM
dti-2593	65	2	.	.	PUNCT
dti-2593	66	1	crossref	crossref	PROPN
dti-2593	66	2	pubmed	pubmed	PROPN
dti-2593	66	3	fig	fig	PROPN
dti-2593	66	4	.	.	PUNCT
dti-2593	67	1	1	1	NUM
dti-2593	67	2	intracranial	intracranial	ADJ
dti-2593	67	3	response	response	NOUN
dti-2593	67	4	to	to	ADP
dti-2593	67	5	sotorasib	sotorasib	PROPN
dti-2593	67	6	assessed	assess	VERB
dti-2593	67	7	with	with	ADP
dti-2593	67	8	magnetic	magnetic	ADJ
dti-2593	67	9	resonance	resonance	NOUN
dti-2593	67	10	imaging	imaging	NOUN
dti-2593	67	11	.	.	PUNCT
dti-2593	68	1	t1	t1	NOUN
dti-2593	68	2	-	-	PUNCT
dti-2593	68	3	weighted	weighted	ADJ
dti-2593	68	4	imaging	imaging	NOUN
dti-2593	68	5	of	of	ADP
dti-2593	68	6	right	right	ADJ
dti-2593	68	7	parietal	parietal	ADJ
dti-2593	68	8	metastasis	metastasis	NOUN
dti-2593	68	9	before	before	ADP
dti-2593	68	10	(	(	PUNCT
dti-2593	68	11	a	a	NOUN
dti-2593	68	12	)	)	PUNCT
dti-2593	68	13	and	and	CCONJ
dti-2593	68	14	after	after	ADP
dti-2593	68	15	(	(	PUNCT
dti-2593	68	16	b	b	NOUN
dti-2593	68	17	)	)	PUNCT
dti-2593	68	18	6	6	NUM
dti-2593	68	19	months	month	NOUN
dti-2593	68	20	of	of	ADP
dti-2593	68	21	sotorasib	sotorasib	NOUN
dti-2593	68	22	;	;	PUNCT
dti-2593	68	23	fluid	fluid	NOUN
dti-2593	68	24	-	-	PUNCT
dti-2593	68	25	attenuated	attenuate	VERB
dti-2593	68	26	inversion	inversion	NOUN
dti-2593	68	27	recovery	recovery	NOUN
dti-2593	68	28	of	of	ADP
dti-2593	68	29	right	right	ADJ
dti-2593	68	30	parietal	parietal	ADJ
dti-2593	68	31	metastasis	metastasis	NOUN
dti-2593	68	32	surrounding	surround	VERB
dti-2593	68	33	edema	edema	NOUN
dti-2593	68	34	before	before	ADV
dti-2593	68	35	(	(	PUNCT
dti-2593	68	36	c	c	NOUN
dti-2593	68	37	)	)	PUNCT
dti-2593	68	38	and	and	CCONJ
dti-2593	68	39	after	after	ADP
dti-2593	68	40	(	(	PUNCT
dti-2593	68	41	d	d	NOUN
dti-2593	68	42	)	)	PUNCT
dti-2593	68	43	6	6	NUM
dti-2593	68	44	months	month	NOUN
dti-2593	68	45	of	of	ADP
dti-2593	68	46	sotorasib	sotorasib	NOUN
dti-2593	68	47	;	;	PUNCT
dti-2593	68	48	t1	t1	VERB
dti-2593	68	49	-	-	PUNCT
dti-2593	68	50	weighted	weighted	ADJ
dti-2593	68	51	imaging	imaging	NOUN
dti-2593	68	52	of	of	ADP
dti-2593	68	53	right	right	ADJ
dti-2593	68	54	frontal	frontal	ADJ
dti-2593	68	55	metastasis	metastasis	NOUN
dti-2593	68	56	before	before	ADP
dti-2593	68	57	(	(	PUNCT
dti-2593	68	58	e	e	NOUN
dti-2593	68	59	)	)	PUNCT
dti-2593	68	60	and	and	CCONJ
dti-2593	68	61	after	after	ADP
dti-2593	68	62	(	(	PUNCT
dti-2593	68	63	f	f	X
dti-2593	68	64	)	)	PUNCT
dti-2593	68	65	6	6	NUM
dti-2593	68	66	months	month	NOUN
dti-2593	68	67	of	of	ADP
dti-2593	68	68	sotorasib	sotorasib	NOUN
dti-2593	68	69	;	;	PUNCT
dti-2593	68	70	t1	t1	VERB
dti-2593	68	71	-	-	PUNCT
dti-2593	68	72	weighted	weighted	ADJ
dti-2593	68	73	imaging	imaging	NOUN
dti-2593	68	74	of	of	ADP
dti-2593	68	75	right	right	ADJ
dti-2593	68	76	cerebellar	cerebellar	ADJ
dti-2593	68	77	metastasis	metastasis	NOUN
dti-2593	68	78	before	before	ADP
dti-2593	68	79	(	(	PUNCT
dti-2593	68	80	g	g	NOUN
dti-2593	68	81	)	)	PUNCT
dti-2593	68	82	and	and	CCONJ
dti-2593	68	83	after	after	ADP
dti-2593	68	84	(	(	PUNCT
dti-2593	68	85	h	h	NOUN
dti-2593	68	86	)	)	PUNCT
dti-2593	68	87	6	6	NUM
dti-2593	68	88	months	month	NOUN
dti-2593	68	89	of	of	ADP
dti-2593	68	90	sotorasib	sotorasib	PROPN
dti-2593	68	91	.	.	PUNCT
dti-2593	69	1	https://doi.org/10.1016/s0140-6736(21)00312-3	https://doi.org/10.1016/s0140-6736(21)00312-3	VERB
dti-2593	69	2	https://www.ncbi.nlm.nih.gov/pubmed/34273294	https://www.ncbi.nlm.nih.gov/pubmed/34273294	NUM
dti-2593	69	3	https://doi.org/10.1056/nejmoa2103695	https://doi.org/10.1056/nejmoa2103695	NOUN
dti-2593	69	4	https://www.ncbi.nlm.nih.gov/pubmed/34096690	https://www.ncbi.nlm.nih.gov/pubmed/34096690	X
dti-2593	69	5	https://doi.org/10.21037/tlcr.2016.11.01	https://doi.org/10.21037/tlcr.2016.11.01	X
dti-2593	69	6	https://www.ncbi.nlm.nih.gov/pubmed/28149755	https://www.ncbi.nlm.nih.gov/pubmed/28149755	X
dti-2593	69	7	https://doi.org/10.1200/jco.2018.78.3118	https://doi.org/10.1200/jco.2018.78.3118	NOUN
dti-2593	69	8	https://www.ncbi.nlm.nih.gov/pubmed/30153097	https://www.ncbi.nlm.nih.gov/pubmed/30153097	ADP
dti-2593	69	9	https://doi.org/10.1093/annonc/mdy405	https://doi.org/10.1093/annonc/mdy405	ADP
dti-2593	69	10	https://www.ncbi.nlm.nih.gov/pubmed/30215676	https://www.ncbi.nlm.nih.gov/pubmed/30215676	NUM
dti-2593	69	11	https://www.ncbi.nlm.nih.gov/pubmed/30215676	https://www.ncbi.nlm.nih.gov/pubmed/30215676	NUM
dti-2593	70	1	https://doi.org/10.1200/po.22.00621	https://doi.org/10.1200/po.22.00621	NOUN
dti-2593	70	2	https://www.ncbi.nlm.nih.gov/pubmed/36809054	https://www.ncbi.nlm.nih.gov/pubmed/36809054	VERB